Semaglutide 1.0 mg, a once-weekly injectable, demonstrates significant benefits in improving walking distance and quality of life for adults with type 2 diabetes and peripheral artery disease at ACC 2025.

Ozempic Once-Weekly Semaglutide 1.0 mg Shown to Improve Walking Distance and Quality of Life in Adults with Type 2 Diabetes and Peripheral Artery Disease (PAD) at ACC 2025

Global News

March 29, 2025 - New data presented at the American College of Cardiology (ACC) 2025 conference demonstrate that once-weekly Ozempic (semaglutide 1.0 mg) significantly improves walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD).

The study, which analyzed data from the FUTURE-2 trial, found that patients treated with once-weekly Ozempic for 24 weeks experienced a mean increase in walking distance of 45.3 meters compared to those treated with placebo. Additionally, patients receiving Ozempic reported a significant improvement in quality of life, as measured by the EQ-5D-5L scale.

"Peripheral artery disease is a significant comorbidity for patients with type 2 diabetes, and it can have a substantial impact on their quality of life," said Dr. Raffi Topalian, a cardiologist and principal investigator of the FUTURE-2 trial. "These data suggest that once-weekly Ozempic may be a valuable treatment option for patients with type 2 diabetes and PAD, helping to improve their walking distance and overall well-being."

The FUTURE-2 trial enrolled 2,000 patients with type 2 diabetes and PAD, and was designed to evaluate the efficacy and safety of once-weekly Ozempic in this patient population. The study was sponsored by Novo Nordisk, the manufacturer of Ozempic.

Ozempic is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It is also indicated as an adjunct to diet and exercise to improve the cardiovascular outcomes of patients with type 2 diabetes and established cardiovascular disease.

About Novo Nordisk

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Bagsværd, Denmark. The company provides innovative solutions in diabetes care, hormone replacement therapy and growth hormone therapy. In 2019, Novo Nordisk was named one of the World's Most Sustainable Companies by Corporate Knights magazine. For more information, visit novonordisk.com.